Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.

Abstract

UNLABELLED The epidermal growth factor receptor (EGFR) is highly expressed in a significant number of human malignancies, and its expression is associated with tumor aggressiveness and overall treatment resistance. The monoclonal antibody cetuximab is increasingly used in clinical settings as a treatment modality in combination with more conventional… (More)
DOI: 10.2967/jnumed.108.054312

Topics

Cite this paper

@article{Aerts2009DisparityBI, title={Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET.}, author={Hugo J. W. L. Aerts and Ludwig J. Dubois and Lars R. Perk and Peter Vermaelen and Guus A. M. S. van Dongen and Bradly G. Wouters and Philippe Lambin}, journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine}, year={2009}, volume={50 1}, pages={123-31} }